ARTES Biotechnology GmbH news

This month ARTES Biotechnology celebrates its 20th anniversary. The whole team is very thrilled and we think it is time to give a small overview on company’s history.

In 2002 at May 10th Michael Piontek founded ARTES as a one-man operation executing and taking care of two license deals as part of a severance agreement. He was absolute sure that this will be an interim solution only while l

Today, Cellumed Co. Ltd., listed stock market company and Germany based ARTES Biotechnology GmbH announce the execution of a Development and License Agreement aiming at the generation of microbial production cell lines, processes and documentation for the cGMP manufacturing of two enzymes required in the manufacturing process of mRNA vaccines.
Under this agreement, ARTES shall be responsible for the development of high yield microbial cell lines expressing two recombinant enzymes. Furthe

ARTES Biotechnology, the German-based biotech company specializing in process development for recombinant vaccines, entered development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP) based platform technologies METAVAX® and SplitCore.

METAVAX® is the company´s platform for the development of vaccines built on enveloped virus-

ARTES Biotechnology GmbH today announced that it has just obtained a renewal of governmental approval for ‘Crédit d’Impôt Recherche’ (CIR) for a next three-year period from the French Ministry of Higher Education and Research (MESR).

The French R&D tax credit CIR gives French companies the ability to claim tax relief on 30% on all generated costs outsourced to ARTES’ R&D services.

“We are pleased to receive th